An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2(nd )or higher line chemotherapy regarding clinical benefit - PANUSCO

BACKGROUND: Pancreatic cancer is an extremely aggressive malignancy. Subjects are afflicted with a variety of disconcerting symptoms, including profound cachexia. Recent data indicate that the outcome of oncological patients suffering from cancer cachexia could be improved by parenteral nutrition an...

Descripción completa

Detalles Bibliográficos
Autores principales: Märten, Angela, Wente, Moritz N, Ose, Jennifer, Büchler, Markus W, Rötzer, Ingeborg, Decker-Baumann, Christiane, Karapanagiotou-Schenkel, Irini, Harig, Sabine, Schmidt, Jan, Jäger, Dirk
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787534/
https://www.ncbi.nlm.nih.gov/pubmed/19943918
http://dx.doi.org/10.1186/1471-2407-9-412

Ejemplares similares

Ejemplares similares